Status:
ENROLLING_BY_INVITATION
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
Lead Sponsor:
Turku University Hospital
Conditions:
Healthy Subjects
Rheumatoid Arthritis
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This study evaluates safety, tolerability, biodistribution and performance of the \[68Ga\]Ga-DOTA-Siglec-9 following a single intravenous administration in patients with active rheumatoid arthritis, v...
Detailed Description
Vascular adhesion protein 1 (VAP-1) is an inflammation inducible endothelial cell molecule mediating leukocyte trafficking from blood into the sites of inflammation. Although VAP-1 plays important rol...
Eligibility Criteria
Inclusion
- Healthy 18-70 year-old men
- Male or female 18-70 year-old patients with active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis
Exclusion
- In healthy: ongoing infection/inflammation proven by blood or other tests
- In patients with rheumatoid arthritis: no treatment with disease-modifying anti-rheumatic drugs or biologic agents, and no corticosteroids for 2 weeks prior the study
- In patients with vasculitis: no immunosuppressives, and glucocorticoid less than 60 mg for 2 weeks or NSAIDs for 1 day prior the study
- In patients with pulmonary sarcoidosis: no corticosteroids for 1 week or NSAIDs for day prior the study
Key Trial Info
Start Date :
November 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03755245
Start Date
November 23 2018
End Date
December 1 2025
Last Update
November 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital, Turku PET Centre
Turku, Finland